BOCA RATON, Fla.--(BUSINESS WIRE)--Aug. 6, 2018--
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its
previously announced $65 million underwritten public offering of common
stock, at a price to the public of $5.10 per share, and concurrent $20
million registered direct offering of common stock to a strategic
investor at a price of $5.10 per share. In connection with the
underwritten public offering, TherapeuticsMD granted the underwriters an
option to purchase up to an additional 1,911,764 shares of common stock
at the public offering price less the underwriting discount, which
option was exercised in full and closed. TherapeuticsMD received net
proceeds from the offerings of approximately $90.0 million, after
deducting underwriting discounts and offering expenses payable by
TherapeuticsMD. All of the shares in the offerings were sold by
TherapeuticsMD intends to use the proceeds of the offerings to fund a
portion of the costs for the commercial launch of its recently FDA
approved product, IMVEXXY™ (estradiol vaginal inserts) for the treatment
of moderate-to-severe dyspareunia (vaginal pain associated with sexual
activity), a symptom of vulvar and vaginal atrophy, due to menopause,
and to fund a portion of the costs for pre-commercialization and
commercialization activities for TX-001HR, its bio-identical hormone
therapy combination of 17ß-estradiol and progesterone in a single, oral
softgel drug candidate, for the treatment of moderate to severe
vasomotor symptoms due to menopause, and its one-year vaginal
contraceptive system candidate in-licensed from the Population Council.
Goldman Sachs & Co. LLC acted as bookrunner for the underwritten public
offering. Cantor Fitzgerald & Co. acted as joint bookrunning manager for
the underwritten public offering. The registered direct offering was
made without an underwriter, placement agent, broker or dealer.
TherapeuticsMD filed shelf registration statements on Form S-3 with the
Securities and Exchange Commission (the “SEC”) with respect to the
offerings. Preliminary prospectus supplements and accompanying
prospectuses related to the offerings were filed with the SEC on July
31, 2018. Final prospectus supplements and accompanying prospectuses
relating to the offerings were filed with the SEC on August 2, 2018.
TherapeuticsMD’s SEC filings are available to the public from the SEC’s
website at www.sec.gov.
Copies of the prospectus supplements and the accompanying prospectuses
relating to these offerings may also be obtained by contacting Goldman
Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY
10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectusfirstname.lastname@example.org;
or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue,
6th Floor New York, New York 10022 or by emailing email@example.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing novel products exclusively for women. Our
products are designed to address the unique changes and challenges women
experience through the various stages of their lives with a therapeutic
focus in family planning/ reproductive health and menopause management.
The company is committed to advancing the health of women and
championing awareness of their healthcare issues.
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that TherapeuticsMD
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
TherapeuticsMD undertakes no duty to update or revise any such
statements, whether as a result of new information, future events or
otherwise. Forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties, many of which
are outside of TherapeuticsMD’s control, that may cause actual results
to differ materially, including the risks and uncertainties associated
with market conditions, risks and uncertainties associated with
TherapeuticsMD’s business and finances in general and other risks
described in the sections titled “Risk Factors” in TherapeuticsMD’s
filings with the SEC, including its most recent Annual Report on Form
10-K, the prospectus supplements with respect to the offerings and other
filings with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180806005415/en/
Source: TherapeuticsMD, Inc.
Ochsner, 561-961-1900 Ext. 2088
Vice President, Investor Relations